Bevanda M, Kelam N, Racetin A, Filipovic N, Bevanda Glibo D, Bevanda I
Medicina (Kaunas). 2024; 60(8).
PMID: 39202484
PMC: 11356070.
DOI: 10.3390/medicina60081202.
Han J, Zhang Q, Lan J, Yu F, Liu J
Front Oncol. 2024; 14:1326292.
PMID: 38406806
PMC: 10889110.
DOI: 10.3389/fonc.2024.1326292.
Banias L, Jung I, Chiciudean R, Gurzu S
Int J Mol Sci. 2022; 23(16).
PMID: 36012726
PMC: 9409470.
DOI: 10.3390/ijms23169455.
Hao M, Wang K, Ding Y, Li H, Liu Y, Ding L
Eur J Med Res. 2022; 27(1):130.
PMID: 35879739
PMC: 9310475.
DOI: 10.1186/s40001-022-00759-z.
Azuwar M, Nor Muhammad N, Afiqah-Aleng N, Mutalib N, Md Yusof N, Mohd Yunos R
Life (Basel). 2022; 12(6).
PMID: 35743803
PMC: 9224961.
DOI: 10.3390/life12060772.
Effects of Inflammatory Response Genes on the Immune Microenvironment in Colorectal Cancer.
Wang Y, Zhang L, Shi G, Liu M, Zhao W, Zhang Y
Front Genet. 2022; 13:886949.
PMID: 35464849
PMC: 9032353.
DOI: 10.3389/fgene.2022.886949.
INHBA is a prognostic predictor for patients with colon adenocarcinoma.
Li X, Yu W, Liang C, Xu Y, Zhang M, Ding X
BMC Cancer. 2020; 20(1):305.
PMID: 32293338
PMC: 7161248.
DOI: 10.1186/s12885-020-06743-2.
Significance of lymph node metastasis in the survival of stage IV colorectal cancer by hematogenous metastasis.
Han E, Kwon Y, Park K, Jeong S, Kang S, Oh J
Ann Surg Treat Res. 2018; 95(4):201-212.
PMID: 30310803
PMC: 6172352.
DOI: 10.4174/astr.2018.95.4.201.
COL1A1: A potential therapeutic target for colorectal cancer expressing wild-type or mutant KRAS.
Zhang Z, Fang C, Wang Y, Zhang J, Yu J, Zhang Y
Int J Oncol. 2018; 53(5):1869-1880.
PMID: 30132520
PMC: 6192778.
DOI: 10.3892/ijo.2018.4536.
Personalizing prognosis in colorectal cancer: A systematic review of the quality and nature of clinical prognostic tools for survival outcomes.
Mahar A, Compton C, Halabi S, Hess K, Weiser M, Groome P
J Surg Oncol. 2017; 116(8):969-982.
PMID: 28767139
PMC: 5760443.
DOI: 10.1002/jso.24774.
Long Non-Coding RNAs As Potential Novel Prognostic Biomarkers in Colorectal Cancer.
Saus E, Brunet-Vega A, Iraola-Guzman S, Pegueroles C, Gabaldon T, Pericay C
Front Genet. 2016; 7:54.
PMID: 27148353
PMC: 4828582.
DOI: 10.3389/fgene.2016.00054.
Colorectal cancer and basement membranes: clinicopathological correlations.
Mylonas C, Lazaris A
Gastroenterol Res Pract. 2015; 2014:580159.
PMID: 25614736
PMC: 4295340.
DOI: 10.1155/2014/580159.
Combined analysis of chromosomal instabilities and gene expression for colon cancer progression inference.
Cava C, Zoppis I, Gariboldi M, Castiglioni I, Mauri G, Antoniotti M
J Clin Bioinforma. 2014; 4(1):2.
PMID: 24456927
PMC: 3931674.
DOI: 10.1186/2043-9113-4-2.
The potential of carcinoembryonic antigen, p53, Ki-67 and glutathion Stransferase-π as clinico-histopathological markers for colorectal cancer.
He Z, Shi C, Wen H, Li F, Wang B, Wang J
J Biomed Res. 2013; 24(1):51-7.
PMID: 23554611
PMC: 3596535.
DOI: 10.1016/S1674-8301(10)60008-5.
DNA topoisomerase II alpha: a favorable prognostic factor in colorectal caner.
Gao X, Yu Z, Zhang C, Bai C, Zheng J, Fu C
Int J Colorectal Dis. 2011; 27(4):429-35.
PMID: 22076611
DOI: 10.1007/s00384-011-1346-x.
Lymphangiogenesis: a new player in cancer progression.
Nagahashi M, Ramachandran S, Rashid O, Takabe K
World J Gastroenterol. 2010; 16(32):4003-12.
PMID: 20731013
PMC: 2928453.
DOI: 10.3748/wjg.v16.i32.4003.
